225 related articles for article (PubMed ID: 26831021)
1. Bence-Jones Protein λ-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Long-term Bortezomib and Dexamethasone Therapy.
Yamaguchi W; Yui N; Nagao T; Oshikawa G; Negi M; Iimori S; Okado T; Rai T; Uchida S
Intern Med; 2016; 55(3):263-8. PubMed ID: 26831021
[TBL] [Abstract][Full Text] [Related]
2. Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.
Bridoux F; Carron PL; Pegourie B; Alamartine E; Augeul-Meunier K; Karras A; Joly B; Peraldi MN; Arnulf B; Vigneau C; Lamy T; Wynckel A; Kolb B; Royer B; Rabot N; Benboubker L; Combe C; Jaccard A; Moulin B; Knebelmann B; Chevret S; Fermand JP;
JAMA; 2017 Dec; 318(21):2099-2110. PubMed ID: 29209721
[TBL] [Abstract][Full Text] [Related]
3. Successful management of hemodialysis-dependent refractory myeloma with modified daratumumab, bortezomib and dexamethasone regimen.
Mizuno S; Kitayama C; Yamaguchi K; Sanada S; Sato T
Int J Hematol; 2020 Dec; 112(6):860-863. PubMed ID: 32710430
[TBL] [Abstract][Full Text] [Related]
4. [Achievement of hemodialysis discontinuation with lenalidomide and dexamethasone therapy in a refractory BJP-type multiple myeloma patient].
Uchida T; Inoue M; Hua J; Hagihara M
Rinsho Ketsueki; 2016 May; 57(5):613-7. PubMed ID: 27263787
[TBL] [Abstract][Full Text] [Related]
5. [Withdrawal of maintenance dialysis in a patient with diagnosed multiple myeloma and renal failure as a consequence of effective anti-tumor treatment].
Rosa J; Sydor A; Jurczyszyn A; Zabawa-Hołyś S; Nowak J; Czapkowicz-Gryszkiewicz L; Sułowicz W
Przegl Lek; 2010; 67(7):547-50. PubMed ID: 21387773
[TBL] [Abstract][Full Text] [Related]
6. Experience of using hemodialysis with medium cut-off dialyzer in cast nephropathy.
Cazorla López JM; García García-Doncel A; Naranjo Muñoz J; Villanego Fernández F; Vigara Sánchez LA; Ceballos Guerrero M
Nefrologia (Engl Ed); 2020; 40(3):367-369. PubMed ID: 32007298
[No Abstract] [Full Text] [Related]
7. A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
Ibata S; Sato T; Kuroda H; Nagamachi Y; Iyama S; Fujimi A; Kamihara Y; Konuma Y; Yoshida M; Tatekoshi A; Hashimoto A; Horiguchi H; Ono K; Murase K; Takada K; Miyanishi K; Kobune M; Hirayama Y; Kato J
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1041-1049. PubMed ID: 27738809
[TBL] [Abstract][Full Text] [Related]
8. Three cases of relapsed/refractory multiple myeloma under hemodialysis treated with panobinostat/bortezomib/dexamethasone (FVD).
Sekiguchi Y; Takizawa H; Inano T; Fukuda Y; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
Int J Hematol; 2017 Oct; 106(4):581-587. PubMed ID: 28353192
[TBL] [Abstract][Full Text] [Related]
9. Outcome of patients with multiple myeloma and renal failure on novel regimens.
Soleymanian T; Soleimani A; Musavi A; Mojtahedi K; Hamid G
Saudi J Kidney Dis Transpl; 2016 Mar; 27(2):335-40. PubMed ID: 26997388
[TBL] [Abstract][Full Text] [Related]
10. Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.
Mizuno S; Kitayama C; Mashiko S; Sanada S
CEN Case Rep; 2022 May; 11(2):265-268. PubMed ID: 34817845
[TBL] [Abstract][Full Text] [Related]
11. [Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].
Fukushima T; Iwao H; Nakajima A; Miki M; Sakai T; Sawaki T; Tanaka M; Masaki Y; Hirose Y; Umehara H
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1387-9. PubMed ID: 19692786
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Psimenou E; Eleutherakis-Papaiakovou E; Migkou M; Matsouka C; Mparmparousi D; Gika D; Kafantari E; Ziogas D; Fotiou D; Panagiotidis I; Terpos E; Kastritis E
Am J Hematol; 2016 May; 91(5):499-502. PubMed ID: 26890495
[TBL] [Abstract][Full Text] [Related]
13. Lambda light chain myeloma with oliguric cast nephropathy and remission with bortezomib, doxorubicin and dexamethasone.
Hada R; Poudyal B; Sharma A; Khatri R
JNMA J Nepal Med Assoc; 2012; 52(188):192-5. PubMed ID: 23591252
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
[TBL] [Abstract][Full Text] [Related]
15. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
[TBL] [Abstract][Full Text] [Related]
16. Sequential kidney and allogeneic hematopoietic stem cell transplantation.
Tanase AD; Sinescu I; Baston C; Tacu D; Domnisor L; Stefan L; Ranete A; Lipan L; Craciun O; Manea I; Bumbea H; Ciurea SO
Am J Hematol; 2019 Oct; 94(10):E267-E270. PubMed ID: 31342545
[No Abstract] [Full Text] [Related]
17. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
Nozza A; Siracusano L; Armando S
Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
[TBL] [Abstract][Full Text] [Related]
18. Hemodialysis: an appropriate therapy in myeloma-induced renal failure.
Sharland A; Snowdon L; Joshua DE; Gibson J; Tiller DJ
Am J Kidney Dis; 1997 Dec; 30(6):786-92. PubMed ID: 9398122
[TBL] [Abstract][Full Text] [Related]
19. Plasma exchange combined with bortezomib-based chemotherapy is effective for early renal recovery in a patient with IgD-λ type multiple myeloma.
Ueda H; Kuno H; Takahashi D; Katsuma A; Kimura A; Nakashima A; Kato J; Momoki M; Ohba R; Dobashi N; Yamamoto I; Kawamura T; Miyazaki Y; Yokoo T
CEN Case Rep; 2020 May; 9(2):165-172. PubMed ID: 31974826
[TBL] [Abstract][Full Text] [Related]
20. [Loss of CD23 expression after bortezomib plus dexamethasone therapy in CCND1/IGH-positive multiple myeloma].
Fujimi A; Hashimoto A; Kanisawa Y; Okuda T; Minami S; Doi T; Matsuno T; Ishikawa K; Uemura N
Rinsho Ketsueki; 2013 Feb; 54(2):224-8. PubMed ID: 23470832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
